Moleculin Biotech, Inc. (MBRX) analyst actions
Rating and price-target actions on MBRX in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the MBRX overview →
2 measured MBRX analyst action events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Moleculin Announces Imminent MIRACLE Trial Unblinding as Blinded Data Continue to Significantly Outperform Historical Benchmarks | Press release | -0.04% | -12.65% | |
| Moleculin Announces New Investigator-Initiated Study of Annamycin for Treating Pancreatic Cancer | Press release | +1.69% | -0.26% |
Keep exploring
More MBRX: earnings → · SEC filings → · MBRX overview →
Other Healthcare names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, plc - Class A Ordinary Shares (KNSA) | 427 | -0.21% | 39% |
| Veracyte, Inc. (VCYT) | 427 | -0.15% | 46% |
| Summit Therapeutics Inc. (SMMT) | 426 | +0.03% | 50% |
| Scholar Rock Holding Corporation (SRRK) | 425 | 0.00% | 49% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.